采用巴曲酶(Batroxobin)脱纤治疗急性脑梗塞70例,痊愈率31.43％,总有效率90％,降低了致残率,与应用706代血浆组比较,差异显著(P<0.01)。巴曲酶是由Bothrops atrox-mojeni经生物工程提纯精制的丝氨酸蛋白酶的巴曲酶单成份制剂,其选择性作用于血中纤维蛋白原,使之在血浆中的浓度降低,从而全血粘稠度下降,增加脑血流量,改善脑供氧,是治疗急性脑梗塞的理想药物。 70 cases of acute cerebral infarction were treated with Batroxobin defibrillation, the cure rate was 31.43%, the total effective rate was 90%, which reduced the morbidity rate. Compared with the 706th generation plasma group, the difference was significant (P <0.01). Batroxobin is a batroxobin single component formulation of purified serine protease from Bothrops atrox-mojeni, which acts selectively on fibrinogen in the blood to reduce its concentration in the plasma, thereby rendering the whole blood thick Decline, increase cerebral blood flow, improve cerebral oxygen supply, is the ideal drug for the treatment of acute cerebral infarction.